Vaccines (Nov 2022)
Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
- Diane Uschner,
- Matthew Bott,
- William H. Lagarde,
- Joseph Keating,
- Hazel Tapp,
- Andrea A. Berry,
- Austin L. Seals,
- Iqra Munawar,
- John Schieffelin,
- Joshua Yukich,
- Michele Santacatterina,
- Mihili Gunaratne,
- Lida M. Fette,
- Brian Burke,
- Greg Strylewicz,
- Sharon L. Edelstein,
- Amina Ahmed,
- Kristen Miller,
- John W. Sanders,
- David Herrington,
- William S. Weintraub,
- Michael S. Runyon,
- on behalf of the COVID-19 Community Research Partnership
Affiliations
- Diane Uschner
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Matthew Bott
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- William H. Lagarde
- Division of Pediatric Endocrinology, Department of Pediatrics, WakeMed Health and Hospitals, Raleigh, NC 27610, USA
- Joseph Keating
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70118, USA
- Hazel Tapp
- Department of Family Medicine, Atrium Health Carolinas Medical Center, Charlotte, NC 28262, USA
- Andrea A. Berry
- Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA
- Austin L. Seals
- Division of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27109, USA
- Iqra Munawar
- Division of Infectious Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27109, USA
- John Schieffelin
- Section of Infectious Disease, Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
- Joshua Yukich
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70118, USA
- Michele Santacatterina
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Mihili Gunaratne
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Lida M. Fette
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Brian Burke
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Greg Strylewicz
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Sharon L. Edelstein
- The Biostatistics Center, George Washington University, Rockville, MD 20852, USA
- Amina Ahmed
- Department of Pediatrics, Atrium Health Levine Children’s Hospital, Charlotte, NC 28203, USA
- Kristen Miller
- MedStar Health Research Institute, Georgetown University, Washington, DC 20007, USA
- John W. Sanders
- Division of Infectious Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27109, USA
- David Herrington
- Division of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27109, USA
- William S. Weintraub
- MedStar Health Research Institute, Georgetown University, Washington, DC 20007, USA
- Michael S. Runyon
- Department of Emergency Medicine, Atrium Health Carolinas Medical Center, Charlotte, NC 28262, USA
- on behalf of the COVID-19 Community Research Partnership
- DOI
- https://doi.org/10.3390/vaccines10111922
- Journal volume & issue
-
Vol. 10,
no. 11
p. 1922
Abstract
We characterize the overall incidence and risk factors for breakthrough infection among fully vaccinated participants in the North Carolina COVID-19 Community Research Partnership cohort. Among 15,808 eligible participants, 638 reported a positive SARS-CoV-2 test after vaccination. Factors associated with a lower risk of breakthrough in the time-to-event analysis included older age, prior SARS-CovV-2 infection, higher rates of face mask use, and receipt of a booster vaccination. Higher rates of breakthrough were reported by participants vaccinated with BNT162b2 or Ad26.COV2.S compared to mRNA-1273, in suburban or rural counties compared to urban counties, and during circulation of the Delta and Omicron variants.
Keywords
